Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C

Swiss Medical Weekly

Volumn 133, Issue 33-34, 2003, Pages 455-460

  August Jörg, Barbara S E ^a   Borovicka, Jan ^a   Dufour, Jean François ^b   Gonvers, Jean Jacques ^c   Henz, Samuel ^a   Hermann, Rudolf ^a,d   Meyenberger, Christa ^a   Weitz, Manfred ^a   Renner, Eberhard L ^d  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Combination therapy; Hepatitis C; Interferon alpha; Relapse; Ribavirin; SASL

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; MENTAL CONCENTRATION; NAUSEA; NEUTROPENIA; NONHUMAN; PILOT STUDY; POLYMERASE CHAIN REACTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VERTIGO; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG COMBINATION; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RECURRENT DISEASE; RETREATMENT; TIME;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; RETREATMENT; RIBAVIRIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0142240117     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72.
2. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;348:825-32.
4. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hürter D, et al. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology 1998;28:1687-95.
5. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-40.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
7. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Eng] J Med 1998;339:1485-92.
8. EASL International Consensus Conference on Hepatitis C. Consensus Statement. Journal of Hepatology 1999;30:956-61.
9. Cammà C, Giunta M, Pinzello G, Morabito A, Verderio P, Pagliaro L. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterology 1999;94:581-95.
10. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. and the Multicenter Study Group. A comparison of three interferon alpha-2b regimes for the long-term treatment of chronic Non-A, Non-B hepatitis. N Engl J Med 1995;332:1457-62.
11. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JE Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration. Hepatology 1996;24:778-89.
12. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. Ann Intern Med 1995;123:897-903.
13. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff L. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26:473-7.
14. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alpha and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatology 1995;23(Suppl 2):8-12.
15. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatology 1997;26:961-6.
16. Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, et al. Long-term efficacy of ribavirin plus interferon alpha in the treatment of chronic hepatitis C. Gastroenterology 1996;111: 1307-12.
17. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O for the Swedish Study Group. Randomized; double blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351: 83-7.
18. Schalm SW, Weiland O, Hansen B, Milella M, Lai MY, Hollander Anna, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
19. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339:1493-9.
20. The METAVIR cooperative group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
21. Bedossa P, Poynard T for the French METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996;24:289-93.
22. Alberti A, Chemello L, Noventa F, Cavalletto L, De Salvo GL. Therapy of hepatitis C: Retreatment with alpha interferon. Hepatology 1997;26(Suppl 1):137S-142S.
23. Payen JL, Izopet J, Galindo-Migeot V, Lauwers-Cances V, Zarski JP, Seigneurin JM, et al. Better efficacy of a 12-month interferon alpha-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial. Hepatology 1998;28:1680-6.
24. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-Interferon in chronic hepatitis C. Hepatology 1995;22:700-6.
25. Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, et al. Re-treatment with interferon alpha of patients with chronic hepatitis C. Hepatology 1998;27:1144-8.
26. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F, et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997; 113:1654-9.
27. Heathcote EJL, Keefe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, et al., and the Consensus Interferon Study Group. Retreatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-43.
28. Di Marco V, Almasio P, Vaccaro A, Ferraro D, Parisi P, Cataldo MG, et al. Combined treatment of relapse of chronic hepatitis C with high-dose alpha-2b interferon plus ribavirin for 6 or 12 months. Journal of Hepatology 2000;33:456-62.